Tax2

Preclinical

AApmonia Therapeutics

Tax2 is one of 4 therapeutic programs targeting Solid Tumor Cancers. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Solid Tumor CancersNot yet recruiting

Solid Tumor CancersPreclinical

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Solid Tumor Cancers

#DrugCompanyPhaseTrials

Vectibix

Amgen

Phase 2

1 2

Lumakras

Amgen

Phase 2

1 3

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Phase 1

1 4

Tax2

AApmonia Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

PreclinicalNot yet recruiting

Solid Tumor Cancers

NCT07688148

Clinical

Trials by Indication[1]

Solid Tumor Cancers1 trial

A Phase 1/2a, First-in-human, Open-label, Dose-escalating Study With a Safety Expansion Cohort to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours

Not yet recruiting·AApmonia Therapeutics·Preclinical·NCT07688148·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tax2. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Tax2. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Apmonia Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: AApmonia Therapeutics

Tax2

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Solid Tumor Cancers1 trial

References

Drug Info

Quick Facts

Related News